BACKGROUND: To evaluate clinical and pathologic response to neoadjuvant docetaxel therapy in patients with stage III breast cancer. PATIENTS AND METHODS: Forty-five patients were planned to receive four cycles of docetaxel 100 mg/m2 every 3 weeks, followed by surgery, four cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (AC) every 3 weeks, radiation therapy (RT), and tamoxifen when indicated. RESULTS: After four cycles of neoadjuvant docetaxel, the clinical response rate within the breast was 59% (95% CI 42% to 73%) and overall (breast and axilla) was 49% (95% CI 38% to 72%) in the intention-to-treat (ITT) population. At the time of surgery, 10% (n=4) of patients had a pathologic complete response (pCR) in the breast, 27% (n=11) had a pCR within the axillary lymph nodes, and 7% (n=3) had a pCR in the breast and axilla (95% CI 2% to 21%). An additional 5% (n=2) had minimal residual invasive tumor (<5 mm). The 5-year overall survival rate was 80%. The percentage of patients with grade 3/4 neutropenia was similar during docetaxel (93%) and AC (86%), while a greater percentage of patients had febrile neutropenia during docetaxel treatment (27%) compared with AC treatment (7%). CONCLUSIONS: Neoadjuvant docetaxel followed by surgery, adjuvant AC, hormonal therapy where indicated, and RT is an active regimen for patients with stage III breast cancer.
BACKGROUND: To evaluate clinical and pathologic response to neoadjuvant docetaxel therapy in patients with stage III breast cancer. PATIENTS AND METHODS: Forty-five patients were planned to receive four cycles of docetaxel 100 mg/m2 every 3 weeks, followed by surgery, four cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (AC) every 3 weeks, radiation therapy (RT), and tamoxifen when indicated. RESULTS: After four cycles of neoadjuvant docetaxel, the clinical response rate within the breast was 59% (95% CI 42% to 73%) and overall (breast and axilla) was 49% (95% CI 38% to 72%) in the intention-to-treat (ITT) population. At the time of surgery, 10% (n=4) of patients had a pathologic complete response (pCR) in the breast, 27% (n=11) had a pCR within the axillary lymph nodes, and 7% (n=3) had a pCR in the breast and axilla (95% CI 2% to 21%). An additional 5% (n=2) had minimal residual invasive tumor (<5 mm). The 5-year overall survival rate was 80%. The percentage of patients with grade 3/4 neutropenia was similar during docetaxel (93%) and AC (86%), while a greater percentage of patients had febrile neutropenia during docetaxel treatment (27%) compared with AC treatment (7%). CONCLUSIONS: Neoadjuvant docetaxel followed by surgery, adjuvant AC, hormonal therapy where indicated, and RT is an active regimen for patients with stage III breast cancer.
Authors: Sylvia Adams; A Bapsi Chakravarthy; Martin Donach; Darcy Spicer; Stella Lymberis; Baljit Singh; Joshua A Bauer; Tsivia Hochman; Judith D Goldberg; Franco Muggia; Robert J Schneider; Jennifer A Pietenpol; Silvia C Formenti Journal: Breast Cancer Res Treat Date: 2010-09-29 Impact factor: 4.872
Authors: Vivek Roy; Barbara A Pockaj; Jacob B Allred; Heidi Apsey; Donald W Northfelt; Daniel Nikcevich; Bassam Mattar; Edith A Perez Journal: Am J Clin Oncol Date: 2013-12 Impact factor: 2.339
Authors: Woo Sung Hong; Ja Young Jeon; Seok Yun Kang; Yong Sik Jung; Ji Young Kim; Mi Sun Ahn; Doo Kyoung Kang; Tae Hee Kim; Hyun Ee Yim; Young-Sil An; Rae Woong Park; Ku Sang Kim Journal: J Korean Surg Soc Date: 2013-06-26
Authors: Piotr Szczepaniak; Mateusz Siedlinski; Diana Hodorowicz-Zaniewska; Ryszard Nosalski; Tomasz P Mikolajczyk; Aneta M Dobosz; Anna Dikalova; Sergey Dikalov; Joanna Streb; Katarzyna Gara; Pawel Basta; Jaroslaw Krolczyk; Joanna Sulicka-Grodzicka; Ewelina Jozefczuk; Anna Dziewulska; Blessy Saju; Iwona Laksa; Wei Chen; John Dormer; Maciej Tomaszewski; Pasquale Maffia; Marta Czesnikiewicz-Guzik; Filippo Crea; Agnieszka Dobrzyn; Javid Moslehi; Tomasz Grodzicki; David G Harrison; Tomasz J Guzik Journal: J Clin Invest Date: 2022-07-01 Impact factor: 19.456